• Explore /
  • Poster
  • / Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials.

Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials.

Abstract Poster

Authors

null

Patrizia Giannatempo

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Patrizia Giannatempo , Jean-Pascal H. Machiels , Naoto Sassa , Jose Angel Arranz Arija , Yasuhisa Fujii , Wen-Pin Su , Bhumsuk Keam , Stephane Culine , Ying-Chun Shen , José Muñoz-Langa , David Leonid Sarid , Maureen J.B. Aarts , Fabio Calabro , Eli Rosenbaum , Olesya Goldman , Blanca Homet Moreno , Abhishek Amar Bavle , Jin Zhi Xu , Sun Young Rha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02256436; NCT02853305

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4512)

DOI

10.1200/JCO.2023.41.16_suppl.4512

Abstract #

4512

Poster Bd #

4

Abstract Disclosures

Similar Posters

First Author: Peter H. O'Donnell

First Author: Michiel Simon Van Der Heijden

First Author: Tibor Csoszi

First Author: Marcus Smith Noel